Inhibrx Biosciences, Inc. (INBX) stock
Close on Nov 11, 2026Market cap $1.33BP/E –Yield –
Inhibrx Biosciences, Inc. grew revenue 550.0% to $1.30M over fiscal 2025. Free cash flow was -$131.90M. At the latest close the market valued the company at $1.33B.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $1.33B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -9.89%
Fundamentals
- Revenue
- $1.30M
- Net income
- -$138.18M
- EPS, diluted
- -$8.88
- Free cash flow
- -$131.90M
- Book value per share
- -$3.38
- Diluted shares
- 16M
Trading
- Next earnings
- Nov 13, 2026 (estimated, after the close)
- Previous close
- $90.61
- Open
- $92.38
- Day's range
- $89.30 – $93.48
- Volume
- 165,738
- Average volume (20 days)
- 298,317
- Index membership
- Russell 2000 (since Dec 2020), Russell 3000 (since Nov 2025)
- Beta (5 years)
- 1.72
- 52-week range
- $57.30 – $155.29
- RSI (14 days)
- 51.7
- Volatility (1 year)
- 82.1%
- Relative volume
- 0.56×
- WACC
- 12.7%
On 4 of our idea lists: Insider cluster buys, Insiders buying the dip, Institutions accumulating, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | INBX | S&P 500 | Difference | INBX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -4.7% | -2.4% | −2.2 pts | ||
| 3 months | -1.9% | -1.2% | −0.8 pts | ||
| Year to date | +14.7% | +12.3% | +2.4 pts | ||
| 1 year | +16.4% | +12.4% | +3.9 pts | ||
| 3 years | +374.3% | +78.8% | +295.5 pts | +68.0% | +21.4% |
| 5 years | +108.2% | +75.2% | +33.0 pts | +15.8% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Inhibrx Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Results
- Update
- Update
About Inhibrx Biosciences
Biological Products, (No Diagnostic Substances)
Inhibrx operates as a clinical-stage biopharmaceutical company focused on discovering and developing novel biologic therapeutic candidates. The company engineers these candidates using proprietary modular protein engineering platforms and single domain antibody technologies designed to address challenging biological targets. Its active clinical pipeline centers on two oncology programs: ozekibart (INBRX-109), a tetravalent DR5 agonist evaluated for chondrosarcoma, Ewing sarcoma, and colorectal adenocarcinoma, and INBRX-106, a hexavalent OX40 agonist investigated for solid tumors such as non-small cell lung cancer and head and neck squamous cell carcinoma. Because its therapeutic candidates are currently in clinical development, the company has no approved commercial products and does not yet serve end customers.
Company profile, executives and historyInhibrx Biosciences stock: common questions
What is Inhibrx Biosciences's stock price?
INBX closed at $90.59 on Nov 11, 2026, down 0.02% on the day. Over the past 52 weeks it traded between $57.30 and $155.29.
What is Inhibrx Biosciences's market cap?
Inhibrx Biosciences was worth $1.33B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is INBX's P/E ratio?
Inhibrx Biosciences lost money over the twelve months to Jun 30, 2026 (diluted EPS -$8.88), so it has no meaningful P/E ratio.
How much revenue does Inhibrx Biosciences make?
Inhibrx Biosciences reported revenue of $1.30M for fiscal 2025, up 550.0% from a year earlier.
Does Inhibrx Biosciences pay a dividend?
No. Inhibrx Biosciences has not paid a cash dividend over the last twelve months.
When does Inhibrx Biosciences report earnings next?
Inhibrx Biosciences is expected to report Q3 FY2026 results on Nov 13, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has INBX stock performed over the past year?
Including dividends, INBX returned +16.4% over the past year, against +12.4% for the S&P 500.
How many INBX shares are sold short?
3M shares were sold short at the latest FINRA report, 35.66% of the float, or 10.0 days of average trading volume.
Who are Inhibrx Biosciences's competitors?
Companies most similar to Inhibrx Biosciences by business, industry and size include CMPX, IMA, CRIS, MOLN, SABS.
See a number that looks wrong?